{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T20:46:30Z","timestamp":1749501990889,"version":"3.37.3"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113068","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T09:11:26Z","timestamp":1725527486000},"page":"113068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"PA","title":["Pirarubicin combined with TLR3 or TLR4 agonists enhances anti-tumor efficiency"],"prefix":"10.1016","volume":"142","author":[{"given":"Ruobing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nai-Peng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiu","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Decheng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenghan","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Hong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.113068_b0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41586-023-06252-9","article-title":"A spatially resolved single-cell genomic atlas of the adult human breast","volume":"620","author":"Kumar","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2024.113068_b0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: Pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.intimp.2024.113068_b0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2024.113068_b0020","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2024.113068_b0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Can. Discov."},{"key":"10.1016\/j.intimp.2024.113068_b0030","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","article-title":"Single-cell map of diverse immune phenotypes in the breast tumor microenvironment","volume":"174","author":"Azizi","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2024.113068_b0035","doi-asserted-by":"crossref","unstructured":"Q. Zhang, M. Sioud, Tumor-associated macrophage subsets: shaping polarization and targeting, Int. J. Mol. Sci. 24 (2023).","DOI":"10.3390\/ijms24087493"},{"key":"10.1016\/j.intimp.2024.113068_b0040","doi-asserted-by":"crossref","first-page":"1049340","DOI":"10.3389\/fimmu.2022.1049340","article-title":"Toll-like receptor-targeted anti-tumor therapies: advances and challenges","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113068_b0045","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","article-title":"Toll-like receptors and the control of immunity","volume":"180","author":"Fitzgerald","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2024.113068_b0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2024.113068_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.812774","article-title":"Toll-like receptor signaling and its role in cell-mediated immunity","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113068_b0060","doi-asserted-by":"crossref","unstructured":"Y. Wang, L. Su, M.D. Morin, et al., Adjuvant effect of the novel TLR1\/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice, in: Proceedings of the National Academy of Sciences of the United States of America, 2018, vol. 115, E8698\u2013e8706.","DOI":"10.1073\/pnas.1809232115"},{"key":"10.1016\/j.intimp.2024.113068_b0065","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.addr.2007.11.005","article-title":"TLR3: interferon induction by double-stranded RNA including poly(I:C)","volume":"60","author":"Matsumoto","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.intimp.2024.113068_b0070","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1158\/0008-5472.CAN-09-1162","article-title":"Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance","volume":"70","author":"Chin","year":"2010","journal-title":"Can. Res."},{"key":"10.1016\/j.intimp.2024.113068_b0075","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1016\/j.molcel.2023.09.009","article-title":"TAK1 is an essential kinase for STING trafficking","volume":"83","author":"Ma","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.intimp.2024.113068_b0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s42003-022-04403-8","article-title":"TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy","volume":"6","author":"Gonzalez","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.intimp.2024.113068_b0085","first-page":"10","article-title":"Toll-like receptor 7\/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer","author":"Ye","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2024.113068_b0090","doi-asserted-by":"crossref","first-page":"6530","DOI":"10.7150\/thno.44417","article-title":"Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma","volume":"10","author":"Zhou","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2024.113068_b0095","doi-asserted-by":"crossref","first-page":"e1177","DOI":"10.1002\/cti2.1177","article-title":"Intratumoral administration of the Toll-like receptor 7\/8 agonist 3M\u2013052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer","volume":"9","author":"Zanker","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.intimp.2024.113068_b0100","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.molimm.2021.12.007","article-title":"The relationship between the efficacy of talazoparib and the functional toll-like receptors 3 and 9 in triple negative breast cancer","volume":"141","author":"Guney Eskiler","year":"2022","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.intimp.2024.113068_b0105","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jconrel.2023.08.006","article-title":"Liposomal co-delivery of toll-like receptors 3 and 7 agonists induce a hot triple-negative breast cancer immune environment","volume":"361","author":"Nguyen","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.intimp.2024.113068_b0110","doi-asserted-by":"crossref","first-page":"1142374","DOI":"10.3389\/fphar.2023.1142374","article-title":"Cationic lipid-assisted nanoparticles for simultaneous delivery of CD47 siRNA and R848 to promote antitumor immune responses","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113068_b0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0022-1759(96)00236-0","article-title":"A murine model of pulmonary damage induced by lipopolysaccharide via intranasal instillation","volume":"202","author":"Szarka","year":"1997","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.intimp.2024.113068_b0120","doi-asserted-by":"crossref","first-page":"1279920","DOI":"10.3389\/fimmu.2024.1279920","article-title":"TRIM28 facilitates type I interferon activation by targeting TBK1","volume":"15","author":"Hua","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113068_b0125","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1631\/jzus.B2000808","article-title":"Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses","volume":"22","author":"Chen","year":"2021","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"10.1016\/j.intimp.2024.113068_b0130","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ccell.2016.06.021","article-title":"Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating alveolar epithelial TLR3 to recruit neutrophils","volume":"30","author":"Liu","year":"2016","journal-title":"Can. Cell"},{"key":"10.1016\/j.intimp.2024.113068_b0135","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13578-023-01038-y","article-title":"FFAR2 antagonizes TLR2- and TLR3-induced lung cancer progression via the inhibition of AMPK-TAK1 signaling axis for the activation of NF-\u03baB","volume":"13","author":"Kim","year":"2023","journal-title":"Cell Biosci."},{"key":"10.1016\/j.intimp.2024.113068_b0140","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2147\/JIR.S348786","article-title":"TLR3 expression is a potential prognosis biomarker and shapes the immune-active tumor microenvironment in esophageal squamous cell carcinoma","volume":"15","author":"Su","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.intimp.2024.113068_b0145","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41420-023-01513-y","article-title":"The TLR3 L412F polymorphism prevents TLR3-mediated tumor cell death induction in pediatric sarcomas","volume":"9","author":"Bisaccia","year":"2023","journal-title":"Cell Death Discovery"},{"key":"10.1016\/j.intimp.2024.113068_b0150","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2024.113068_b0155","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1126\/science.282.5396.2085","article-title":"Defective LPS signaling in C3H\/HeJ and C57BL\/10ScCr mice: mutations in Tlr4 gene","volume":"282","author":"Poltorak","year":"1998","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.intimp.2024.113068_b0160","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/80833","article-title":"Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus","volume":"1","author":"Kurt-Jones","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2024.113068_b0165","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.4049\/jimmunol.168.6.2939","article-title":"Toll-like receptor 4-MD-2 complex mediates the signal transduction induced by flavolipin, an amino acid-containing lipid unique to Flavobacterium meningosepticum","volume":"168","author":"Gomi","year":"2002","journal-title":"J. Immunol. (Baltimore, Md: 1950)"},{"key":"10.1016\/j.intimp.2024.113068_b0170","doi-asserted-by":"crossref","first-page":"304ra142","DOI":"10.1126\/scitranslmed.aaa3863","article-title":"Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity","volume":"7","author":"Modhiran","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2024.113068_b0175","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.cell.2011.09.051","article-title":"CD14 controls the LPS-induced endocytosis of Toll-like receptor 4","volume":"147","author":"Zanoni","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2024.113068_b0180","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1126\/science.1085536","article-title":"Toll-like receptor signaling pathways","volume":"300","author":"Barton","year":"2003","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.intimp.2024.113068_b0185","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1080\/07853890.2022.2095664","article-title":"The role of toll-like receptors (TLRs) in pan-cancer","volume":"54","author":"Huang","year":"2022","journal-title":"Ann. Med."},{"key":"10.1016\/j.intimp.2024.113068_b0190","doi-asserted-by":"crossref","first-page":"e27633","DOI":"10.2196\/27633","article-title":"Web-based survival analysis tool tailored for medical research (KMplot): development and implementation","volume":"23","author":"L\u00e1nczky","year":"2021","journal-title":"J. Med. Internet Res."},{"key":"10.1016\/j.intimp.2024.113068_b0195","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1158\/0008-5472.CAN-17-3480","article-title":"Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner","volume":"78","author":"Wanderley","year":"2018","journal-title":"Can. Res."},{"key":"10.1016\/j.intimp.2024.113068_b0200","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4049\/jimmunol.175.1.342","article-title":"Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences","volume":"175","author":"Stout","year":"2005","journal-title":"J. Immunol. (Baltimore, Md: 1950)"},{"key":"10.1016\/j.intimp.2024.113068_b0205","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.biomaterials.2012.09.062","article-title":"Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers","volume":"34","author":"Huang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.intimp.2024.113068_b0210","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.3389\/fimmu.2018.02520","article-title":"Both type I and type II interferons can activate antitumor M1 Macrophages when combined with TLR stimulation","volume":"9","author":"M\u00fcller","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113068_b0215","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1158\/0008-5472.CAN-16-0294","article-title":"Impact of pattern recognition receptors on the prognosis of breast cancer patients undergoing adjuvant chemotherapy","volume":"76","author":"Vacchelli","year":"2016","journal-title":"Can. Res."},{"key":"10.1016\/j.intimp.2024.113068_b0220","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1186\/1471-2407-10-665","article-title":"Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis","volume":"10","author":"Gonz\u00e1lez-Reyes","year":"2010","journal-title":"BMC Can."},{"key":"10.1016\/j.intimp.2024.113068_b0225","first-page":"786","article-title":"Expression profile of Toll-like receptors in human breast cancer","volume":"21","author":"Shi","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.intimp.2024.113068_b0230","doi-asserted-by":"crossref","first-page":"E3216","DOI":"10.1073\/pnas.1420811112","article-title":"TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth","volume":"112","author":"Haricharan","year":"2015","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2024.113068_b0235","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2024.113068_b0240","first-page":"vi46-vi51","article-title":"Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents","volume":"23 Suppl 6","author":"Andr\u00e9","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2024.113068_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.125295","article-title":"CircEGFR reduces the sensitivity of pirarubicin and regulates the malignant progression of triple-negative breast cancer via the miR-1299\/EGFR axis","volume":"244","author":"Ma","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.intimp.2024.113068_b0250","article-title":"CircZCCHC2 decreases pirarubicin sensitivity and promotes triple-negative breast cancer development via the miR-1200\/TPR axis","volume":"27","author":"Zhang","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.intimp.2024.113068_b0255","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s40425-019-0563-7","article-title":"Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial","volume":"7","author":"Li","year":"2019","journal-title":"J. Immunother. Can."},{"key":"10.1016\/j.intimp.2024.113068_b0260","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/cas.12824","article-title":"Adjuvant for vaccine immunotherapy of cancer\u2013focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity","volume":"106","author":"Seya","year":"2015","journal-title":"Can. Sci."},{"key":"10.1016\/j.intimp.2024.113068_b0265","doi-asserted-by":"crossref","first-page":"1075291","DOI":"10.3389\/fimmu.2023.1075291","article-title":"A novel defined TLR3 agonist as an effective vaccine adjuvant","volume":"14","author":"Ko","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113068_b0270","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-022-01515-x","article-title":"Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer","volume":"21","author":"Huang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2024.113068_b0275","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2024.113068_b0280","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1038\/s41388-022-02496-3","article-title":"Intralesional TLR4 agonist treatment strengthens the organ defense against colonizing cancer cells in the brain","volume":"41","author":"Blazquez","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2024.113068_b0285","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/path.4958","article-title":"High-mobility group box 1 released by autophagic cancer-associated fibroblasts maintains the stemness of luminal breast cancer cells","volume":"243","author":"Zhao","year":"2017","journal-title":"J. Pathol."},{"key":"10.1016\/j.intimp.2024.113068_b0290","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jamaoncol.2016.6007","article-title":"Topical imiquimod plus nab-paclitaxel for breast cancer cutaneous metastases: a phase 2 clinical trial","volume":"3","author":"Salazar","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2024.113068_b0295","doi-asserted-by":"crossref","unstructured":"A.P. Runde, R. Mack, P.B. S J, J. Zhang, The role of TBK1 in cancer pathogenesis and anticancer immunity, J. Exp. Clin. Can. Res: CR 41 (2022) 135.","DOI":"10.1186\/s13046-022-02352-y"},{"key":"10.1016\/j.intimp.2024.113068_b0300","article-title":"TBK1 is paradoxical in tumor development: a focus on the pathway mediating IFN-I expression","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113068_b0305","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/s12276-022-00893-y","article-title":"Pim1 promotes IFN-\u03b2 production by interacting with IRF3","volume":"54","author":"Ko","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.intimp.2024.113068_b0310","doi-asserted-by":"crossref","first-page":"e2403019","DOI":"10.1002\/advs.202403019","article-title":"SHISA3 reprograms tumor-associated macrophages toward an antitumoral phenotype and enhances cancer immunotherapy","author":"Zhang","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.intimp.2024.113068_b0315","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2024.113068_b0320","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41568-024-00674-x","article-title":"Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity","volume":"24","author":"Meier","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2024.113068_b0325","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1021\/acs.molpharmaceut.6b00932","article-title":"Inducing optimal antitumor immune response through coadministering iRGD with pirarubicin loaded nanostructured lipid carriers for breast cancer therapy","volume":"14","author":"Deng","year":"2017","journal-title":"Mol. Pharm."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924015893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924015893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T02:54:10Z","timestamp":1728010450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924015893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":65,"alternative-id":["S1567576924015893"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113068","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pirarubicin combined with TLR3 or TLR4 agonists enhances anti-tumor efficiency","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113068"}}